The construction of the manufacturing facility is progress (although it wouldn't even be necessary for a normal biotech startup, which could outsource the manufacturing). But it's not an excuse for not getting tox testing started on time, which we were assured could be done with Flucide produced in the current lab.
but then they don't see any of the obvious clues.... including a stock price that is now up 5 fold off the Feb lows. Stocks are forward looking while the detractors here are always rearward looking. Perhaps that view will change when the stock is... maybe $5 or so?
Market Data 
Markets 
AI
